Immutep Limited announces that data from its TACTI-002 Phase II trial evaluating the chemo-free combination of eftilagimod alpha and KEYTRUDA in 1st line non-small cell lung cancer has been accepted for a Mini Oral presentation at the 2023 European Society for Medical Oncology Congress that will be held in Madrid, Spain from 20-24 October 2023. The presentation will include more mature overall survival data, following on from the data announced on 17 May 2023. Additionally, data from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF evaluating efti in conjunction with anti-PD-1 therapy and doublet chemotherapy in non-squamous 1L NSCLC, has been accepted for a poster presentation. Also, a Trial in Progress poster for the EFTISARC-NEO investigator-initiated Phase II trial evaluating efti with pembrolizumab and radiotherapy in soft tissue sarcoma will be presented.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMP:
- Immutep announces first patient enrolled, dosed in EFTISARC-NEO trial
- First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
- Immutep secures third U.S. patent for eftilagimod alpha
- Immutep completes A$80M capital raise
- Immutep granted U.S. patent for IMP761
